Comment on CMS-2026-1255-0001
American Academy of Allergy Asthma and ImmunologySupportAdvocacy
Summary: The American Academy of Allergy, Asthma & Immunology (AAAAI) supports the proposed rules for electronic prior authorization standards, improved transparency, and expanded public reporting of prior authorization metrics. However, the organization opposes the removal of drug formulary information from specific APIs and urges CMS to establish a uniform 24-hour maximum response timeframe for prior authorization requests.
See attached